Navigation Links
Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
Date:1/14/2010

STOCKHOLM, January 14 /PRNewswire/ -- Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.

"We are very excited about BioChromix Pharma as they have a novel approach that targets the cause of the disease. This is an important addition to our portfolio", says Conny Bogentoft, CEO of Karolinska Development.

"We have a clear goal - to bring our lead product candidates for Alzheimer's disease to the market. Being part of the Karolinska Development portfolio, will provided direct access to a broad network of key competencies and resources in the pharmaceutical industry which will be of great importance for us in order to succeed", says Peter Asberg, CEO of BioChromix Pharma AB.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products. http://www.karolinskadevelopment.com'/>"/>

SOURCE Karolinska Development AB (publ), and BioChromix AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
2. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
3. Karolinska Development Closes Fully Subscribed New Share Issue
4. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
5. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
6. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
7. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
8. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
9. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
10. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
11. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) September 30, 2014 New applications ... arrangements that have evolved in nature over millennia are ... bioinspired materials for applications in biophotonics in the ... . The journal is published by SPIE, the international ... Library. Several of the peer-reviewed articles are accessible via ...
(Date:10/1/2014)... TeselaGen Biotechnology has received a ... their bioCAD/CAM software suite, which uses synthetic biology ... Business Innovation Research Phase II grant will be used ... from the Lawrence Berkeley National Laboratory. j5 was developed ... laboratory that develops alternative fuel technologies for the Department ...
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... in German . ... (TUM) have demonstrated a new kind of building block ... computer chips could be based on three-dimensional arrangements of ... technology of the semiconductor industry CMOS fabrication of ... and collaborators at the University of Notre Dame are ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... of a second generation oral niacin receptor agonist,under a ... of atherosclerosis and other disorders. The initiation of this,trial ... very pleased with the progress of this collaboration,investigating the ...
... 2 to 3 children in 100 are born with a ... but in 80% of the cases scientists do not know ... Katholieke Universiteit Leuven, in collaboration with an Australian research team, ... mental retardation is caused by a twofold production of two ...
... Cardica, Inc.,(Nasdaq: CRDC ) today reported financial ... quarter and six months ended December 31, 2007., ... with over 1,000,C-Port systems shipped in the past ... designed to enable minimally-invasive cardiac surgery and,substantial advancement ...
Cached Biology Technology:Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3Discovery of new cause of mental retardation simplifies search for treatments 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
(Date:9/30/2014)... . , Animals ... such as exposure to predators. Researchers from the Max ... study on different populations of great tits that risk-taking ... High metabolic rates and low temperatures were associated with ... more likely to approach potential predators. , The readiness ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... NEW YORK CITY (May 14, 2010)--The New York ... $27 million from the Robertson Foundation, established by Julian ... addition to other support, will provide funding for NYSCF-Robertson ... and the creation of the NYSCF-Robertson Stem Cell Prize. ...
... to have a higher risk of getting sick compared to ... crew quarters, being away from family and friends and a ... sleep - are known to wreak havoc on the immune ... at the University of Arizona has discovered that spaceflight changes ...
... Scientists studying the environmental impact of Hurricane Katrina on ... New Orleans have revealed the ecological impact and human ... published in a special issue of Environmental Toxicology ... ecological damage by altering coastal chemistry and habitat. ...
Cached Biology News:Immune system compromised during spaceflight, study finds 2Immune system compromised during spaceflight, study finds 3New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3
... Dodeca cell with multi-casting chamber is used for ... mini format handcast (8.3 x 7.3 cm) or ... requires 3.4-4.4 L of buffer and includes an ... to an external refrigerated circulator (not included), lid ...
...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
...
Biology Products: